Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer reagents such as mitoxantrone, 7-ethyl-10-hydroxycamptothecin, and topotecan. We reported previously that estrone and 17␤-estradiol reverse BCRP-mediated multidrug resistance. In the present study, we demonstrate that BCRP exports estrogen metabolites. First, we generated BCRP-transduced LLC-PK1 (LLC/BCRP) cells, in which exogenous BCRP is expressed in the apical membrane, and investigated transcellular transport of 3 H-labeled compounds using cells plated on microporous filter membranes. The basal-to-apical transport (excretion) of mitoxantrone, estrone, and 17␤-estradiol was greater in LLC/ BCRP cells than in LLC-PK1 cells. Thin-layer chromatography of transported steroids revealed that the transport of estrone and 17␤-estradiol was independent of BCRP expression. Alternatively, increased excretion of estrone sulfate and 17␤-estradiol sulfate was observed in LLC/BCRP cells. BCRP inhibitors completely inhibited the increased excretion of sulfated estrogens across the apical membrane. Conversion of estrogens into their sulfate conjugates was similar between LLC/BCRP and LLC-PK1 cells, suggesting that the increased excretion of estrogen sulfates was attributable to BCRP-mediated transport. Next, the uptake of 3 H-labeled compounds in membrane vesicles from BCRP-transduced K562 (K562/BCRP) cells was investigated.
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3 H-labeled estrone sulfate, but not 3 H-labeled estrone or 17␤-estradiol, was taken up by membrane vesicles from K562/BCRP cells, and this was ATP-dependent. Additionally, BCRP inhibitors suppressed the transport of estrone sulfate in membrane vesicles from K562/BCRP cells. These results suggest that BCRP does not transport either free estrone or 17␤-estradiol but exports sulfate conjugates of these estrogens.
Breast cancer resistance protein (BCRP) is a member of the ATP-binding cassette transporter G family and is also known as ABCG2 or ABCP. BCRP mediates concurrent resistance to such chemotherapeutic agents as mitoxantrone (MXR), SN-38 (an active metabolite of CPT-11), and topotecan, presumably by pumping these reagents out of the cell, thereby resulting in concentrations lower than cytotoxic levels (Allikmets et al., 1998; Doyle et al., 1998; Maliepaard et al., 1999; Miyake et al., 1999; Kawabata et al., 2001) .
Although the function of BCRP as a drug transporter has been intensively investigated, there is still much to be elucidated concerning its physiological role. BCRP is normally expressed in a wide variety of organs such as placenta, intestine, liver, ovary, testis, kidney, brain and also in hematopoietic stem cells (Allikmets et al., 1998; Doyle et al., 1998; Zhou et al., 2001 ). In particular, BCRP is highly expressed in the syncytiotrophoblasts of the placenta (Maliepaard et al., 2001 ). In our previous screening for chemicals that circumvent BCRP-mediated drug resistance, estrone (E 1 ) and 17␤-estradiol (E 2 ) were found to effectively restore drug sensitivity in BCRP-transduced K562 (K562/BCRP) cells (Imai et al., 2002) . In light of the function of the syncytiotrophoblasts that synthesize and secrete these estrogens in a mother's body, E 1 and E 2 are therefore candidates as physiological substrates of BCRP.
The present study was designed to examine the direct transport of both E 1 and E 2 . First, we performed a transcellular transport assay by using BCRP-transfected LLC-PK1 cells, which form a highly polarized monolayer in either a culture dish or on a membrane filter (Ueda et al., 1992; Evers et al., 1996; Jonker et al., 2000) . Exogenous BCRP is expressed in the apical membrane of the BCRP-transfected LLC-PK1 cells (Jonker et al., 2000) . The BCRP-mediated transcellular transport of 3 H-labeled MXR and specific steroids was investigated. The effect of specific compounds on MXR or estrogen transport by BCRP was also examined. Next, the uptake of 3 H-labeled compounds in membrane vesicles from K562/BCRP cells was investigated, as was the effect of compounds on estrone 3-sulfate (E 1 S) transport by BCRP. The results from these experiments have provided information that will help in our understanding of the physiological functions of BCRP, in addition to its interaction with steroids and other compounds. Establishment of LLC/BCRP Cells. LLC-PK1 cells, the epithelial cells of the porcine kidney, were cultured in M199 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. LLC-PK1 cells were transduced with an HaBCRP retrovirus supernatant (Imai et al., 2002) . Cells were then treated with increasing doses of MXR (2, 4, and 8 nM) for 17 days to enrich the transduced cells. The resulting mixed population of MXR-resistant cells, LLC/BCRP, was used in this study. Expression of BCRP was confirmed by Western blot analysis with the anti-BCRP polyclonal antibody 3488, as described previously (Kage et al., 2002) . Anticancer drug resistance levels of BCRP-expressing cells were evaluated by the examination of cell-growth inhibition after incubation at 37°C for 5 days in the presence of various concentrations of anticancer drugs. In addition, the effects of BCRP inhibitors on MXR sensitivity were investigated. Cell numbers were determined with a Coulter counter (Beckman Coulter, Inc., Fullerton, CA). The IC 50 values were determined from growth inhibition curves.
Materials and Methods

Reagents
Transcellular Transport Assay. Exponentially growing cells were plated on 3-m pore Transwell 3414 filters (Costar, Cambridge, MA) at a density of 2.4 ϫ 10 6 cells/well and cultured for 3 days. Culture medium in both the upper and lower wells was replaced with 2 ml of serum-free M199 medium 1.5 h before the experiments. The medium in either the upper or lower well was then replaced with 2 ml of medium containing 3 H-labeled compounds and/or 14 C-labeled inulin. The cells were incubated at 37°C in 5% CO 2 , and 50 l of the medium from the opposite side was sampled after 1, 2, and 4 h from the addition of 3 H-labeled compounds and/or 14 C-labeled inulin. Radioactivity of each sample was measured by liquid scintillation counting and presented as a percentage fraction of the total radioactivity before incubation. All data were presented as mean values with standard deviations of triplicate determinations from three different cultures. The inhibitory effect of the compounds on the transcellular transport of either 3 H-labeled MXR or steroids was examined by adding the compounds to both wells 1.5 h before beginning the experiments. The subsequent procedure was as described above.
Ether Extraction and Silica-Gel Thin-Layer Chromatography of Transported Steroids. Transported 3 H-labeled steroids were analyzed by ether extraction and silica-gel TLC. The experimental procedure was the same as that of the transepithelial transport assay until sample collection. At 0.5 or 1 h after the addition of [ 3 H]E 1 or [ 3 H]E 2 , all 2 ml of medium in the opposite side was collected, and the total radioactivity was determined from 50 l of each sample. Thereafter, free estrogens were separated from estrogen metabolites by diethyl ether. In this condition, free estrogens are extracted to the organic phase, and sulfate or glucuronide conjugates of estrogens remain in the aqueous phase (Mellor and Hobkirk, 1975) . Radioactivities in the organic fraction (free estrogens) and the aqueous fraction (estrogen metabolites) were then measured. The total radioactivity before the ether extraction and the radioactivity in the aqueous fraction of transported 3 H-labeled estrogens are presented as percentage fractions of the radioactivity before the incubation.
For silica-gel TLC, the experimental procedure was the same as that of the transepithelial transport assay until sample collection. A 50-l sample of the medium in the apical side after 1-and 2-h incubations was mixed with 100 l of methanol, spotted, and run simultaneously with standard unlabeled estrogens and derivatives (100 g each) on silica-gel 60 F 254 plates (Merck, Darmstadt, Germany) (Imai et al., 2002) . Membrane vesicles were prepared according to the method described previously (Naito et al., 1988) . Briefly, K562 or K562/BCRP cells (2 ϫ 10 9 ) were suspended in 32 ml of hypotonic buffer [10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 1.5 mM MgCl 2 , 1 mM 4-(2-aminoethyl)-benzensulfonyl fluoride, and 20 g/ml aprotinin] and homogenized using a Dounce homogenizer. The homogenate was centrifuged at 200g for 10 min. The supernatant was overlaid on 35% sucrose solution buffered with 10 mM Tris-HCl, pH 7.4, and centrifuged at 45,000g for 60 min. The membrane fraction at the interface was collected and precipitated by centrifugation at 138,000g for 60 min. The pellet (membrane vesicles) was resuspended in 10 mM Tris-HCl, pH 7.4, and 250 mM sucrose. The membrane vesicles were diluted to protein concentrations of 2 or 5 mg/ml, aliquoted, and stored at Ϫ80°C until use.
Intravesicular Transport Assay. The intravesicular transport assay was performed by a rapid centrifugation technique. Vesicles were thawed quickly at 37°C and kept on ice. The transport reaction mixture (50 l) contained 50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 250 mM sucrose, 10 mM phosphocreatine, and 100 g/ml creatine phosphokinase, with or without 5 mM ATP, radiolabeled and unlabeled compounds, and membrane vesicles (50 g of protein). The amount of membrane vesicles was increased to 200 g/reaction in the [ 3 H]E 2 17G uptake experiment. First, the transport reaction mixture was kept on ice for 5 min. Then the reaction tube was incubated at 37°C for an appropriate time. The reaction was terminated by placing the tube on ice and adding 1 ml of ice-cold stop solution (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 250 mM sucrose). The membrane vesicles were precipitated by centrifugation at 18,000g for 10 min at 4°C. The pellet was solubilized with 100 l of 0.1 M NaOH and then neutralized by the addition of 0.1 M HCl. The radioactivity was counted with the use of a liquid scintillation counter.
Statistical Analysis. The two-sided unpaired Student's t test was used to evaluate the statistical significance of the differences between the two sets of data. The difference was considered significant when the p value was less than 0.05.
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Results
Establishment of LLC/BCRP Cells. BCRP expression in LLC/BCRP cells, a mixed culture of stable transformants, was examined by Western blot analysis in the presence of reducing agents. Under these conditions, BCRP was detected as a monomer of 70 kDa (Fig. 1A) . The BCRP expression level in LLC/BCRP cells was stable for at least 2 months without any further drug selection. LLC/BCRP cells were five to six times more resistant to MXR and SN-38 than were the parental LLC-PK1 cells (Fig. 1B) . Fumitremorgin C (FTC), an inhibitor of BCRP, and E 1 reversed the MXR resistance of LLC/BCRP cells (Fig. 1B) (Rabindran et al., 2000) , which were as sensitive as LLC-PK1 cells in the presence of 3 M FTC. E 1 (10 M) circumvented the MXR resistance of LLC/ BCRP cells, although LLC/BCRP cells remained more resistant than LLC-PK1 cells. E 2 also showed similar effects on the MXR resistance of LLC/BCRP cells (data not shown). These growth-inhibition assays suggested that the parental LLC-PK1 cells expressed endogenous MXR transporters that were sensitive to FTC and E 1 . However, exogenous BCRP expression in LLC/BCRP cells conferred far stronger anticancer drug resistance than did the endogenous transporters, which can also be suppressed by FTC and E 1 . 14 C]inulin appearance in the other side were less than 1% of the total radioactivity per hour ( Fig. 2A) . The IC 50 values of MXR for LLC-PK1 and LLC/BCRP cells in a 5-day treatment were 0.58 and 2.7 nM, respectively (Fig. 1B) . However, treatment of the cells with 50 nM MXR for 4 h did not result in [
14 C]inulin leakage, suggesting that the cells maintained a monolayer structure during the experimental Fig. 2A) (Fig. 2D) (Tsuruo et al., 1981; Cole et al., 1994 We demonstrated previously that BCRP-mediated drug resistance was overcome by E 1 and E 2 (Imai et al., 2002) . The inhibitory effect of steroids on BCRP-mediated drug transport was validated by a transcellular transport assay of [ 3 H]MXR. LLC/BCRP and LLC-PK1 cells showed similar sensitivity to E 1 , E 2 , or progesterone. The IC 50 values of E 1 , E 2 , and progesterone in a 5-day treatment were approximately 22, 10, and 12 M, respectively. Transcellular transport experiments using [ 3 H]MXR (50 nM) with steroids (up to 50 M) did not result in [
14 C]inulin leakage, suggesting that the cells maintained a monolayer structure during the experimental period of 4 h (data not shown). E 2 (30 M) strongly suppressed the BCRP-dependent increase in MXR excretion (Fig. 2E ). E 1 also suppressed the BCRP-dependent increase in MXR excretion (data not shown). The BCRP-dependent increase in MXR excretion was not affected by progesterone (50 M), in accordance with our previous result that progesterone was unable to surmount BCRP-mediated drug resistance ( Fig. 2F) (Imai et al., 2002) .
Transcellular Transport of Steroids in LLC/BCRP Cells. Because our previous study raised the possibility that E 1 and E 2 were in fact substrates of BCRP, the transcellular transport of 3 H-labeled estrogens was investigated.
[ 3 H]E 1 excretion in LLC/BCRP cells was greater than that in LLC-PK1 cells, whereas its reabsorption in LLC/BCRP cells was reduced compared with that in LLC-PK1 cells (Fig. 3A) at the later time points (2 and 4 h) suggested that there was metabolic modification of these steroids. To examine this possibility, radioactive compounds that appeared on the other side after a 0.5-or 1-h incubation were extracted with diethyl ether. In this analysis, 99% of free estrogen was extracted in the organic fraction, and 99% of conjugated estrogens remained in the aqueous fraction. The ether-nonextractable radioactivity in the excretion medium of LLC/BCRP cells was higher than that of LLC-PK1 cells (Fig. 4A) . The increased excretion of the ether-nonextractable 3 H-labeled compounds in LLC/BCRP cells was suppressed in the presence of 3 M FTC, so that excretion of the ether-nonextractable 3 H-labeled compounds became identical between LLC/BCRP and LLC-PK1 (Fig. 4A) . Additionally, the ether-nonextractable radioactivity in the reabsorption medium of LLC/BCRP cells was lower than that in LLC-PK1 cells (Fig. 4B) . In contrast, there was no significant difference in the ether-extractable radioactivity in both excretion and reabsorption between LLC/BCRP and LLC-PK1, and FTC did not affect excretion of the ether-extractable fraction in both cell lines (data not shown).
Silica-Gel TLC Analysis of Transported Steroids. (Fig. 5) . In the transport assay of [ 3 H]E 1 , excretion of E 1 S was significantly greater in LLC/BCRP cells than that in LLC-PK1 cells (Fig. 5A ). In the transport assay of [ 3 H]E 2 , excretion of E 2 S was significantly greater in LLC/ BCRP cells than that in LLC-PK1 cells (Fig. 5B ). In addition, there was no significant difference in the reabsorption of free /well) were plated on 3-m pore filters 3 days before beginning the experiment. 3 H-labeled steroids were added in either the apical or the basal side of the medium. After 1, 2, and 4 h, the percentage of radioactivity that appeared in the opposite side was measured. Subcellular Localization of Exogenous BCRP in LLC-PK1 Cells. Immunohistochemical analysis of BCRP in LLC/BCRP cells showed very faint fluorescence in the membrane. Therefore, we constructed EGFP-BCRP to confirm the localization of BCRP in the transfected LLC-PK1 cells. Expression of an EGFP-BCRP fusion protein in LLC/EGFP-BCRP cells was detected as a 100-kDa band by Western blotting under reducing conditions with an anti-BCRP antibody (Fig. 6A) . This 100-kDa protein also reacted with an anti-GFP antibody (data not shown). LLC/EGFP-BCRP cells displayed resistance to SN-38 and MXR and increased basalto-apical transport of [ 3 H]MXR compared with LLC-PK1 cells (Fig. 6B) . LLC/EGFP-BCRP cells showed increased basal-to-apical transport of 3 H-labeled estrogens compared with LLC-PK1 cells, although this transport activity was somewhat weaker than in LLC/BCRP cells (data not shown). 5 . Silica-gel TLC analysis of excreted 3 H-labeled estrogens and their metabolites. The experimental procedure was the same as that of the transepithelial transport assay until sample collection. Medium (50 l) in the apical side after either a 1-or 2-h incubation was mixed with 100 l of methanol, spotted, and run simultaneously with standard unlabeled estrogens and derivatives (100 g each) on silica-gel plates in chloroform/ methanol/acetic acid (8:3:1). Separated zones, visualized under ultraviolet, were cut, and their radioactivities were counted. A, excreted EGFP-BCRP was identified in the apical membrane of the cells using fluorescence microscopy (Fig. 6C) 
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at ASPET Journals on June 16, 2017 molpharm.aspetjournals.org pendent but saturable (Fig. 8B) . The K m and V max values of this uptake were calculated by Eadie-Hofstee plots as 6.8 Ϯ 1.4 M and 1.4 Ϯ 0.3 nmol/min/mg protein, respectively.
Effect of Physiological Steroids on E 1 S Uptake. The effects of physiological steroids and their metabolites on BCRP-dependent [ 3 H]E 1 S uptake were tested (Fig. 9) . In a comparison of the two estrogens, E 2 showed a stronger inhibitory effect than did E 1 . Among the estrogen derivatives examined, E 1 S showed the strongest inhibitory effect. The inhibitory effects of E 2 and E 2 S, however, proved to be almost the same. Estrogen glucuronides did not show any significant inhibition of BCRP-mediated [ 3 H]E 1 S uptake, which was also the case for progesterone and cortisol. Dehydroepiandrosterone sulfate showed stronger BCRP inhibition than did dehydroepiandrosterone. Taurolithocholate and taurolithocholate sulfate showed stronger inhibition of the BCRP-mediated [
3 H]E 1 S uptake than did taurocholate. These results show that sulfate-conjugated steroids have high affinity with BCRP.
Discussion
LLC-PK1 cells have been used to characterize the drugtransporting properties of P-gp, MRP1, and BCRP because they retain high polarity in culture dishes. Exogenous P-gp and BCRP are expressed in the apical membrane, whereas exogenous MRP1 is expressed in the basolateral membrane of LLC-PK1 cells (Ueda et al., 1992; Evers et al., 1996; Jonker et al., 2000) . were rapidly converted into sulfate conjugates in both cell lines and that BCRP-dependent increased excretion and decreased reabsorption of 3 H-labeled estrogens was caused by BCRP-mediated transport of estrogen sulfates. The strong inhibition of increased excretion of 3 H-labeled estrogen metabolites by FTC in LLC/BCRP cells also indicated BCRP-mediated excretions of estrogen sulfates. When other steroids were analyzed, we found that BCRP transduction had no effect on the transport of cortisol and progesterone. Because cortisol is excreted by P-gp expressed in LLC-PK1 cells, P-gp activity was similar between LLC-PK1 and LLC/BCRP (Ueda et al., 1992) . Therefore, the increased excretion of estrogen sulfates was not associated with P-gp in LLC/BCRP cells. Transcellular transport assays using [ 3 H]E 1 S showed no difference in transport between LLC/BCRP and LLC-PK1. [
3 H]E 1 S cannot freely pass through cell membranes because it is highly hydrophilic. BCRP, expressed on the cell surface, mediates ATP-dependent transport of substrates from the intracellular space to the outside of the cells; therefore, it does not transport sulfated estrogens placed outside of the cells.
LLC-PK1 cells are epithelial cells of the proximal tubule of the porcine kidney and naturally express several transporters. In this study, parental LLC-PK1 cells excreted MXR beyond the reabsorption level, and this excretion was strongly suppressed by both FTC and estrogens. This excretion was barely inhibited by VRP, and these results are indicative of an endogenous MXR transporter in the apical membrane of LLC-PK1 cells. The results of the drug sensitivity test also suggested the existence of an endogenous transporter that effluxed MXR in LLC-PK1 cells. BCRP ex- pression analysis of mammals revealed that it was strongly expressed in the kidney, even more highly than in the placenta (Jonker et al., 2000) . Taken together, we conclude from these data that an endogenous porcine homolog of BCRP was expressed in the apical membrane of LLC-PK1 cells. In addition, other transporters were expressed in the basolateral membrane of LLC-PK1 and LLC/BCRP cells and mediated the reabsorption of E 1 S and E 2 S. Reabsorption of 3 H-labeled estrogen metabolites increased in the presence of FTC and decreased in the presence of VRP (data not shown). Therefore, we also conclude that the transporters may contain a porcine homolog of MRP1 (Cole et al., 1994; Evers et al., 1996) .
To further verify BCRP-mediated transport of estrogen and the corresponding metabolites, the uptake of 3 H-labeled estrogens in membrane vesicles from K562/BCRP cells was investigated. For this purpose, we chose a rapid centrifugation technique in which approximately 10% of the membrane protein was consistently recovered as a pellet in every reaction tube. The recovery rate of membrane protein was similar to that in a rapid filtration method using Millipore membranes (10 -15%) (Naito et al., 1988) . This figure seems to be low, but our recovery rate was always uniform, and the background radioactivity was usually approximately 1 to 2% of the total radioactivity in the reaction mixture. In our assay system, therefore, reproducible results with minor scattering were obtained.
BCRP (Fig. 7) . ATP-dependent uptake of [ 3 H]E 1 S was, however, observed in K562/ BCRP membrane vesicles with a K m value of 6.8 Ϯ 1.4 M but not in vesicles from K562 cells. This ATP-dependent uptake was inhibited by the BCRP substrate anticancer agent SN-38 and the BCRP inhibitor FTC, suggesting that the transport is mediated by BCRP (Fig. 7) . When the sucrose concentration in the transport reaction mixture was increased to 1 M, the [ 3 H]E 1 S uptake decreased to 60% of that measured in the presence of 250 mM sucrose. This result suggests that a fraction of [ 3 H]E 1 S was actually incorporated into the inner space of K562/BCRP membrane vesicles. MRP1 is also known to transport E 1 S stimulated in the presence of glutathione (Qian et al., 2001 ). The K m values of E 1 S transport by MRP1 in the presence or absence of 1 mM glutathione were reported to be 0.73 and 4.2 M, respectively. In our system however, glutathione at 1 mM did not stimulate [ 3 H]E 1 S uptake into K562/BCRP membrane vesicles (data not shown).
Various steroidal compounds were shown to inhibit [ 3 H]E 1 S uptake into K562/BCRP membrane vesicles (Fig. 9) . Among the noncharged steroids, E 2 showed a stronger inhibitory effect than either E 1 , dehydroepiandrosterone, progesterone, or cortisol. Among steroid metabolites, glucuronides showed a marginal effect on [ 3 H]E 1 S uptake into K562/BCRP membrane vesicles. The ATP-dependent uptake of [ 3 H]E 2 17G did not seem to be mediated by BCRP (Fig. 7) . Therefore, glucuronides are not likely to be substrates for BCRP. In contrast, E 1 S, E 2 S, dehydroepiandrosterone sulfate, taurolithocholate, and taurolithocholate sulfate strongly inhibited [ 3 H]E 1 S uptake. These data suggest therefore that these sulfated steroidal compounds interact with BCRP and may be exported by BCRP.
Free E 1 and E 2 both blocked intravesicular E 1 S uptake by BCRP (Fig. 9) . . They do not have steroid structures, and some of them do not have residues to be sulfated. Therefore, at least some of these compounds block the function of BCRP in these native forms. It is not clear, however, whether these antiestrogens would be transported by BCRP.
We hitherto have provided evidence that indicates BCRPmediated export of estrogen sulfates. Very recently, other groups have reported intravesicular uptake of estrogen metabolites by membrane vesicles from BCRP-expressing cells (Chen et al., 2003; Suzuki et al., 2003) . BCRP is widely expressed in tissues and organs such as intestine, liver, hematopoietic stem cells, and vessels other than urogenital organs, and the physiological function of BCRP is not likely to be restricted to the transport of estrogen sulfates (Doyle et al., 1998; Maliepaard et al., 2001; Zhou et al., 2001 ). To our knowledge, E 1 S is the first compound identified as a physiological substrate transported by BCRP with a similar affinity and capacity as MRP1. Recently, it was reported that Bcrp1Ϫ/Ϫ mice did not manifest any detectable gross abnormalities, were fertile, and produced litters of normal size (Zhou et al., 2002) . However, another lineage of Bcrp1Ϫ/Ϫ mice displayed photosensitivity, and indeed, BCRP has been implicated in the transport of chlorophyll-derived dietary phototoxin and protoporphyrin in hematopoietic stem cells and erythrocytes (Jonker et al., 2002) . Further investigation will be needed to thoroughly clarify the physiological role of BCRP.
Cells expressing point mutants of BCRP containing Thr482, Gly482, or Met482 instead of Arg482 (wild-type) have been found to show altered substrate recognition and increased drug resistance against MXR and doxorubicin (Honjo et al., 2001; Ozvegy et al., 2002; Wang et al., 2003) . We therefore started to examine the functional consequences of BCRP Arg482 mutations and recently made 15 Arg482 mutant BCRP cDNA transfectants. Surprisingly, 13 of 15 mutants showed higher resistance to MXR and doxorubicin (M. Miwa, S. Tsukahara, E. Ishikawa, S. Asada, Y. Imai, and Y. Sugimoto, unpublished findings). The transporting activity of estrogen sulfates by these mutant BCRPs is now under further investigation in our laboratory. In conclusion, we find that BCRP is not associated with the transport of free E 1 and E 2 , but it can physiologically transport sulfated conjugates of estrogens.
